SecSonar.com

Roivant Sciences Ltd. (ROIV)

Roivant Sciences Ltd. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Roivant Sciences Ltd. (ROIV) is a Biotechnology company based in GB with a market capitalization of $21.7B. Revenue declined 71.6% year-over-year and free cash flow was negative at -$758.6M. This page tracks ROIV's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

GB · 908 employees · IPO Dec 8, 2020

Valuation

Valuation & price

$29.96 · as of May 23, 2026 · -15.3% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

4.80

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$35.13$22.94$10.74Jul 25Dec 25Jul 26Jul 7, 25$10.74Jul 9, 25$11.22Jul 11, 25$11.36Jul 15, 25$11.36Jul 17, 25$11.65Jul 21, 25$11.48Jul 23, 25$11.39Jul 25, 25$11.55Jul 29, 25$11.42Jul 31, 25$11.36Aug 4, 25$11.51Aug 6, 25$11.65Aug 11, 25$11.17Aug 13, 25$11.96Aug 15, 25$11.85Aug 19, 25$11.76Aug 21, 25$11.81Aug 25, 25$11.64Aug 27, 25$11.99Aug 29, 25$11.93Sep 3, 25$12.59Sep 5, 25$12.92Sep 9, 25$13.48Sep 11, 25$14.41Sep 16, 25$14.18Sep 18, 25$15.09Sep 22, 25$14.94Sep 24, 25$14.70Sep 26, 25$15.17Sep 30, 25$15.13Oct 2, 25$15.98Oct 6, 25$16.26Oct 8, 25$16.03Oct 10, 25$16.04Oct 14, 25$16.40Oct 16, 25$17.11Oct 21, 25$17.87Oct 23, 25$18.12Oct 27, 25$18.81Oct 29, 25$18.76Oct 31, 25$19.99Nov 4, 25$19.87Nov 6, 25$20.57Nov 10, 25$21.17Nov 12, 25$21.32Nov 14, 25$20.29Nov 18, 25$20.52Nov 20, 25$20.27Nov 25, 25$20.86Nov 28, 25$20.81Dec 2, 25$20.10Dec 4, 25$21.18Dec 8, 25$20.99Dec 10, 25$20.24Dec 12, 25$22.10Dec 16, 25$22.94Dec 18, 25$21.79Dec 22, 25$22.68Dec 24, 25$22.50Dec 29, 25$21.70Jan 2, 26$21.93Jan 6, 26$21.61Jan 8, 26$21.78Jan 12, 26$22.16Jan 14, 26$23.81Jan 16, 26$23.13Jan 21, 26$22.98Jan 23, 26$22.58Jan 27, 26$22.53Jan 29, 26$22.02Feb 2, 26$21.94Feb 4, 26$21.65Feb 9, 26$27.67Feb 11, 26$26.80Feb 13, 26$26.45Feb 18, 26$27.48Feb 20, 26$27.15Feb 24, 26$28.26Feb 26, 26$28.49Mar 2, 26$28.10Mar 4, 26$29.52Mar 6, 26$28.78Mar 10, 26$29.70Mar 12, 26$28.55Mar 17, 26$28.30Mar 19, 26$27.80Mar 23, 26$27.93Mar 25, 26$27.36Mar 27, 26$26.52Mar 31, 26$27.70Apr 2, 26$28.33Apr 7, 26$27.75Apr 9, 26$28.48Apr 13, 26$28.95Apr 15, 26$29.39Apr 17, 26$29.83Apr 22, 26$29.15Apr 24, 26$27.41Apr 28, 26$27.77Apr 30, 26$28.53May 4, 26$28.36May 6, 26$28.82May 8, 26$28.56May 12, 26$29.39May 14, 26$29.50May 18, 26$28.55May 20, 26$32.41May 22, 26$29.96May 28, 26$29.88Jun 1, 26$29.09Jun 3, 26$28.70Jun 5, 26$28.58Jun 9, 26$29.05Jun 11, 26$29.73Jun 15, 26$30.03Jun 17, 26$31.20Jun 22, 26$31.25Jun 24, 26$34.01Jun 26, 26$34.07Jul 2, 26$35.13
$10.7452-week range$35.39
Loading valuation history…

Fundamentals

Key fundamentals

$21.7B

Market cap

-71.6%

Revenue growth (YoY)

84.4%

Gross margin

-$758.6M

Free cash flow (USD)

-$4.2B

Net debt

Net cash position

-4.3%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2020 → 2026

FY 2020$67.7MFY 2021$23.8MFY 2022$55.3MFY 2023$31.5MFY 2024$32.7MFY 2025$29.1MFY 2026$8.3M
$67.7M$8.3M

Free cash flow by year

2020 → 2026

FY 2020$-766.7MFY 2021$-557.9MFY 2022$-695.2MFY 2023$-856.1MFY 2024$-766.6MFY 2025$-844.0MFY 2026$-758.6M
-$766.7M-$758.6M

Gross margin by year

2022 → 2026

FY 202283.8%FY 202390.4%FY 202495.1%FY 202596.9%FY 202684.4%
83.8%84.4%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

11

Insider sells · 90 days

Earnings

Last reported: May 20, 2026 (EPS $-0.28)

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $349KFitzgerald Meghan · Director · $349KJul 2, 2026Filing
  • Insider sellInsider Sell $610KEpperly Melissa B, · Director · $610.3KJul 1, 2026Filing
  • Insider sellInsider Sell $49.4MGold Daniel Allen · Director · $49.4MJun 30, 2026Filing
  • Insider sellInsider Sell $56.4MMANCHESTER KEITH S · Director · $56.4MJun 30, 2026Filing
  • Insider sellInsider Sell $49.4MQVT Financial LP · $49.4MJun 30, 2026Filing
  • Insider sellInsider Sell $34.1MSukhatme Mayukh · Director, President & CIO · $34.1MJun 29, 2026Filing
  • Insider sellInsider Sell $6.6MVenker Eric · President & Immunovant CEO · $6.6MJun 26, 2026Filing
  • Insider sellInsider Sell $6.1MVenker Eric · President & Immunovant CEO · $6.1MMay 22, 2026Filing
  • 8-K eventEarnings ReleaseMay 20, 2026Filing
  • Annual report10-K FiledMay 20, 2026Filing

Questions

Frequently asked questions

What is Roivant Sciences Ltd.'s market cap?

Roivant Sciences Ltd. (ROIV) has a market capitalization of $21.7B.

What is ROIV's P/E ratio?

A meaningful P/E ratio is not available for ROIV — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is ROIV's price-to-book (P/B) ratio?

ROIV trades at 4.80 times book value per share.

When did Roivant Sciences Ltd. last report earnings?

ROIV last reported earnings on May 20, 2026; the next date is not yet scheduled.

Are insiders buying ROIV stock?

SEC Form 4 filings show no open-market insider buys at Roivant Sciences Ltd. in the last 90 days (11 sells).

Same arena

Related companies in Biotechnology

INSM

Insmed Incorporated

$23.3B

UTHR

United Therapeutics Corporation

$23.4B

RPRX

Royalty Pharma plc

$23.6B

INCY

Incyte Corporation

$19.5B

MRNA

Moderna, Inc.

$19.3B

GMAB

Genmab A/S

$16.3B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.